Dave Sather of Sather Financial Group presented his investment thesis on UnitedHealth Group (US: UNH) at Wide-Moat Investing Summit 2026.
Thesis summary:
UnitedHealth Group is the largest health insurer in the United States and one of the “most hated” companies in the country. It comprises two parts: UnitedHealthcare, which underwrites risk and insures roughly 50.9 million members, ahead of Elevance at 45.2 million; and Optum, which owns clinics, physicians, data, and pharmacy infrastructure. Optum Health employs or contracts about 90,000 physicians, roughly 10% of the US workforce; Optum Insight holds the largest de-identified clinical and claims database, covering about 330 million people, 9 of 10 hospitals, and 4 of 5 health plans; and Optum Rx is the third-largest PBM at about 23% share. Dave frames the combination as a flywheel: Optum’s data sharpens UnitedHealthcare’s underwriting, and the same tools are sold to other participants.
The moat rests on scale and predictive data, evidenced by a best-in-class MLR averaging 82.8% over the past decade. Dave notes the moat was tested when Haven, the 2018 Amazon, Berkshire, and JPMorgan JV, tried to displace managed care and disbanded by 2021. Todd Combs, its driving force, later bought UNH stock for Berkshire. Dave views Morningstar’s narrow-moat rating as misplaced.
The shares recently traded near where they sat five years ago, weighed down by the Change Healthcare cyberattack, the CEO murder, a DOJ billing probe, Medicare Advantage rate fears, and PBM reform. Dave argues these are largely cyclical or overstated. A late-2025 Humana ruling barring sample extrapolation undercuts the $26 billion liability figure, and the 2027 MA final rate came in better than feared. The core issue, elevated post-COVID utilization, is short-tail and reprices every 12 months.
Returning CEO Stephen Hemsley, the architect of modern UNH, is repricing the book, exiting international and unprofitable accounts, shrinking enrollment, and pushing an AI-first agenda funded by $1.5 billion in 2026 at an expected 2:1 return. His pay is almost entirely stock options with three-year cliff vesting, and he has replaced 50 of the top 100 leaders.
Dave’s earnings-based two-stage DCF, using a 16x exit P/E, an 11.5% discount rate, an MLR improving to 85% by 2028, and roughly 12% EPS CAGR, supports about $460 against a recent quote near $409. EPS recently ran about $16.29 while FCF exceeded $21 per share. Management’s 13% to 16% EPS targets imply a $482 to $600 range. Dave sees about 10% downside against about 50% upside.
Disclaimer
Wide-Moat Investing Summit 2026 was held from June 23-26, 2026. The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.
Slides
Let’s take a closer look.
